Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 106 to 120 of 215 results for arthritis

  1. Otilimab for treating moderate to severe rheumatoid arthritis [ID6171]

    Discontinued Reference number: GID-TA11108

    Technology appraisal guidance
    Discontinued

  2. Osteoarthritis in over 16s (QS87)

    This quality standard covers diagnosing, assessing and managing osteoarthritis in adults aged over 16. It includes treatment and support, and referral for joint surgery. It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    19 October 2022
    View quality statements

    Sections for QS87

  3. Systemic juvenile idiopathic arthritis: canakinumab (ESNM36)

    This evidence summary has been withdrawn. An NHS England clinical commissioning policy statement on biologic therapies for the treatment of juvenile idiopathic arthritis is available.

    Withdrawn advice

  4. Technology appraisal committee D members

    Find out more about NICE technology appraisals advisory committee D members

  5. Technology appraisal committee D members

    Find out more about NICE technology appraisals advisory committee D members

  6. Psoriatic arthritis (moderate to severe) - leflunomide [ID391]

    Discontinued Reference number: GID-TAG385

    Technology appraisal guidance
    Discontinued

  7. Filgotinib for treating moderately to severely active ulcerative colitis (TA792)

    Evidence-based recommendations on filgotinib (Jyseleca) for moderately to severely active ulcerative colitis in adults when conventional or biological treatment cannot be tolerated, or the disease has responded inadequately or lost response to treatment.

    Technology appraisal guidance
    Published
    1 June 2022
    View recommendations

    Sections for TA792

  8. Rituximab for the treatment of rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs [ID333]

    Discontinued Reference number: GID-TAG418

    Technology appraisal guidance
    Discontinued

  9. NICE recommended that research should be carried out to determine the relationship between activity and prosthesis failure.

    guidance Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hip Number TA304 Date issued February 2014

    Research recommendation
    Published
    9 June 2015

  10. Denosumab for the prevention of osteoporotic fractures in postmenopausal women (TA204)

    Evidence-based recommendations on denosumab (Prolia) for preventing osteoporotic fragility fractures in postmenopausal women.

    Technology appraisal guidance
    Published
    27 October 2010
    View recommendations

    Sections for TA204

  11. Subcutaneous methotrexate:- What is the clinical and cost effectiveness of subcutaneous methotrexate compared with oral methotrexate for adults with early onset RA starting a new DMARD?

    Source guidance details Comes from guidance Rheumatoid arthritis in adults: management Number NG100 Date issued July

    Research recommendation
    Published
    11 December 2018

  12. Infliximab for acute exacerbations of ulcerative colitis (TA163)

    Evidence-based recommendations on infliximab (Remicade) for treating acute exacerbations of severely active ulcerative colitis in adults.

    Technology appraisal guidance
    Published
    17 December 2008
    View recommendations

    Sections for TA163

  13. NICE recommended the collection of data on prosthesis failure or on the prevalence of people living with a failed hip but for whom revision surgery is not suitable or who choose not to have revision surgery. NICE further recommended that nomenclature for hip replacement failure needs to be established to allow demarcation of prosthesis-dependent and prosthesisindependent hip replacement failure. Furthermore, patient reported outcome measures collected as part of the National Joint Registry should allow for reporting of hip replacement failure in people who cannot or choose not to have revision surgery.

    guidance Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hip Number TA304 Date issued February 2014

    Research recommendation
    Published
    9 June 2015

  14. NICE agreed that further research would be of value to investigate factors which can predict the likelihood of rapid progression of disease and response to treatment with biological DMARDs. Factors to investigate include:- persistent elevation of inflammatory markers (such as C-reactive protein [CRP]) and- presence of erosions on X-ray and- positive for anti-citrullinated protein antibodies (ACPA).

    certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after...

    Research recommendation
    Published
    15 March 2016

  15. Cox-II inhibitors for the treatment of osteoarthritis and rheumatoid arthritis [ID388]

    Discontinued Reference number: GID-TAG372

    Technology appraisal guidance
    Discontinued